The ELF Stakeholder Meeting brought together more than 90 participants from 60 different organisations, based in 14 different countries, reflecting the European aspect of ELF. The participants represent a broad group of involved stakeholders…
Drug Discovery Hub Dortmund (DDHD) is the name of the new initiative at the Zentrum für integrierte Wirkstoffforschung (ZIW) of the TU Dortmund University (TU), which got started on 1 April 2018. Scientists from eight institutions combine their manifold expertise to…
Dortmund Alliance Receives 11 Million Euros for the Development of New Lead Compounds Read More »
The project consortium comprises 30 partners, including academic institutions, small and medium-sized enterprises (SMEs) and pharmaceutical companies. The team also includes seven members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)…
European Commission says: ELF is leading the way to discovering new medicines Read More »
Many patients who suffer strong or persistent pain receive inadequate relief from therapy. Improving pharmacotherapy and management for refractory pain is a so enormously complex problem that only concerted…
Dr. Alexander Piechot, Chief Operating Officer, interviewed by European Pharmaceutical Review Magazine on Taros’ success story since 1999 and its choice to invest into Agilent’s Preparative Scale Purification and UHPLC-MS system, a truly automated LC/MS-system supporting analytical and preparative purification…
Taros featured in European Pharmaceutical Review Read More »
Pioneering ideas to improve antidepressant therapies are greatly required since existing antidepressants are moderately effective and the response rate in patients suffering from depression is approximately less than 50%. Moreover, 5-10% of patients show no response to treatments. Custom Research Organization (CRO) Taros…
Tackling unmet medical needs Read More »
Nature magazine article on compound acquisition Buying cheap can be very expensive in the end Compound acquisition: „Buying cheap can be very expensive in the end“, says Dimitrios Tzalis, CEO of Taros Chemicals and Chemistry Leader of the EU Lead Factory in Nature magazine 548, 485–488, doi:10.1038/548485a. Read the full article – “check your chemistry” About Taros Chemicals
Nature magazine article on compound acquisition Read More »
Acquiring chemotypes beholding structural features of natural products, for instance high sp3 character, the synthesis of compound collections based on core-scaffolds of natural products presents a promising strategy in drug discovery…
Taros Chemicals, a privately owned CRO focused on serving the needs of pharmaceutical, chemical, agrochemical and biotech companies, announced that in November this year, it achieved the benchmark of the delivery of 30,000 unprecedented chemical compounds to be used for…
Taros: 30,000 novel chemical compounds shipped to the ELF Read More »
The European Lead Factory aims to accelerate the development of innovative medicines. It’s a unique partnership between the world of researchers , the pharmaceutical industry and SMEs such as Taros, where flexibility and creativity are fundamental. “We are producing chemical compounds, that are going to be introduced into…
euronews BUSINESS PLANET visit @ Taros Read More »
Content
Contact
Taros Chemicals GmbH & Co. KG
Emil-Figge-Str. 76a
44227 Dortmund
GERMANY
© 2022 Taros Chemicals GmbH & Co. KG. All rights reserved.
